Vyleesi (Bremelanotide) Safety in Adults Aged 30 to 49

How Bremelanotide Works and Why Safety Matters for This Age Group

Bremelanotide activates melanocortin-4 (MC4R) receptors in the central nervous system to increase sexual desire. Unlike flibanserin, which requires daily dosing, bremelanotide is used on-demand via a prefilled autoinjector (FDA prescribing information). That on-demand dosing pattern shapes the safety conversation: each injection produces a discrete pharmacological window rather than steady-state drug exposure.

Women aged 30 to 49 represent the core population studied in the RECONNECT trials and the demographic most commonly diagnosed with HSDD. This age bracket also coincides with the emergence of cardiovascular risk factors, early metabolic changes, and polypharmacy related to contraception or mental-health treatment. The result is that safety evaluation in this group must account for drug interactions, hemodynamic effects, and the reality that many patients use bremelanotide alongside SSRIs, hormonal contraceptives, or antihypertensives.

The RECONNECT program enrolled 1,247 premenopausal women across two Phase 3, randomized, double-blind, placebo-controlled trials (Kingsberg et al., Obstet Gynecol 2019). Roughly 95% of participants fell within the 25-to-50 age window, making this dataset directly applicable to the 30-to-49 cohort.

Nausea: The Most Frequent Adverse Event

Nausea occurred in 40.0% of bremelanotide-treated patients compared to 1.3% receiving placebo in RECONNECT [1]. That number is high on paper. The clinical reality is more nuanced.

Most nausea episodes were rated mild to moderate. Onset was typically within 30 to 45 minutes of injection. Resolution usually happened within two hours. Only 1.6% of trial participants discontinued because of nausea, meaning that the vast majority of women who experienced it found the symptom tolerable enough to continue treatment (FDA prescribing information).

The prescribing information recommends that patients take an antiemetic if nausea has occurred with prior doses. Ondansetron 4 mg taken 30 minutes before the bremelanotide injection is a common off-label approach used in clinical practice. A second strategy is ensuring that the injection is not given on an empty stomach.

Nausea frequency also decreased with repeated dosing. Women who continued into the open-label extension phase reported lower nausea rates over time, suggesting a habituation effect (Kingsberg et al., Obstet Gynecol 2019). For patients in the 30-to-49 range managing work schedules and family responsibilities, knowing that nausea is front-loaded and tends to improve is clinically relevant information.

Blood Pressure and Cardiovascular Considerations

Bremelanotide produces a transient blood-pressure increase. In the RECONNECT trials, the mean rise was approximately 6 mmHg systolic and 3 mmHg diastolic, peaking 2 to 3 hours after injection and returning to baseline by 12 hours [1]. Heart rate increased by a mean of 5 to 6 beats per minute during the same window.

Those numbers matter. The FDA label carries a specific contraindication against use in women with uncontrolled hypertension or known cardiovascular disease (FDA prescribing information). Women aged 30 to 49 increasingly carry diagnoses of prehypertension, especially those with obesity, PCOS, or family history of early cardiovascular events.

No serious cardiovascular adverse events were reported in the RECONNECT program. No myocardial infarction, stroke, or sustained arrhythmia occurred in the bremelanotide arm. The FDA's post-marketing surveillance requirements include ongoing monitoring of cardiovascular signals, but through 2025 no new safety signals have emerged from FAERS data (FDA FAERS database).

For prescribers, the practical step is confirming that blood pressure is controlled before initiating therapy. The American College of Obstetricians and Gynecologists defines controlled hypertension as readings consistently below 140/90 mmHg on current therapy (ACOG Practice Bulletin). Women meeting that threshold are not excluded from bremelanotide use, but periodic blood-pressure reassessment is prudent.

Hyperpigmentation and Skin Changes

Focal skin darkening occurred in approximately 1% of patients in the RECONNECT trials [1]. Bremelanotide activates MC1R in addition to MC4R, and MC1R is the receptor responsible for melanin synthesis in melanocytes.

Hyperpigmentation appeared most commonly on the face, gingiva, and breasts. In most cases it was mild and did not lead to treatment discontinuation. The FDA label notes that resolution after stopping the drug has not been well-characterized, meaning that pigment changes could persist (FDA prescribing information).

For women aged 30 to 49, this adverse effect intersects with conditions like melasma, which is already common in this demographic due to hormonal contraceptive use and pregnancy history. Dermatologic screening before initiation and periodic skin checks at follow-up visits are reasonable clinical steps, particularly for patients with Fitzpatrick skin types III through VI who may be more susceptible to pigmentary changes.

Injection-Site Reactions and Administration Safety

Bremelanotide is delivered via the Oksana autoinjector to the abdomen or thigh. Injection-site reactions occurred in 5.4% of patients in RECONNECT, compared to 4.3% in the placebo group [1]. Reactions included bruising, erythema, and transient pain.

Self-injection technique matters. The autoinjector simplifies the process compared to a manual syringe, but proper rotation of injection sites prevents lipodystrophy. Storage requirements are straightforward: the drug should be kept at room temperature (20, 25°C) and protected from light.

One practical concern for women in the 30-to-49 age range is injection timing in the context of a busy schedule. The drug should be administered at least 45 minutes before anticipated sexual activity. Unlike daily medications, there is no fixed-time dosing schedule to remember or forget. This "event-driven" model reduces overall drug exposure but requires advance planning.

Drug Interactions Relevant to the 30-to-49 Population

The FDA label identifies one clinically meaningful interaction: bremelanotide decreases naltrexone absorption by approximately 50% when the two drugs are taken together. Women using naltrexone for alcohol-use disorder or opioid-use disorder should avoid concurrent bremelanotide or separate dosing by at least 12 hours (FDA prescribing information).

Formal interaction studies with oral contraceptives showed no clinically significant pharmacokinetic changes. Bremelanotide did not alter the AUC or Cmax of ethinyl estradiol or levonorgestrel at the 1.75 mg dose. Women using combined oral contraceptives, progestin-only pills, or hormonal IUDs do not need dose adjustments.

SSRI and SNRI co-administration was common in RECONNECT. Approximately 17% of enrolled women were taking an antidepressant at baseline. Sub-group analysis showed no increase in adverse events among SSRI/SNRI users, and no serotonin-syndrome signals were detected [1]. Given that SSRIs themselves can cause sexual dysfunction (a known contributor to secondary HSDD), this finding is especially relevant for the 30-to-49 population where antidepressant use is prevalent.

Alcohol interaction data are limited. The prescribing information does not include a specific alcohol warning, but given the transient blood-pressure effect, clinicians often advise moderation with alcohol on the day of use.

Long-Term Safety Data

The open-label extension of RECONNECT followed patients for up to 52 weeks of as-needed bremelanotide use. The safety profile remained consistent with the 24-week core study. No new adverse-event categories emerged. Nausea frequency declined. Hyperpigmentation prevalence did not increase substantially with extended use (Kingsberg et al., Obstet Gynecol 2019).

Mean dosing frequency in the open-label phase was approximately 2 to 3 injections per month. That is well below the 8-dose-per-month ceiling. The low actual-use frequency limits cumulative drug exposure and likely contributes to the favorable long-term safety data.

Weight changes were not clinically significant. Despite MC4R's role in energy homeostasis, the intermittent, low-dose subcutaneous administration of bremelanotide did not produce the appetite-suppressive or weight-loss effects seen with chronic MC4R agonism in animal models. Body weight remained stable across both the core and extension phases [1].

No signals of hepatotoxicity, nephrotoxicity, or immunogenicity appeared in the extension data. Routine laboratory monitoring is not required per the FDA label.

Comparing Bremelanotide Safety to Flibanserin

The two FDA-approved HSDD treatments for premenopausal women have fundamentally different safety profiles. Flibanserin (Addyi) requires daily dosing and carries a boxed warning about severe hypotension and syncope when combined with alcohol or moderate-to-strong CYP3A4 inhibitors (FDA Addyi label). Bremelanotide has no alcohol contraindication and no boxed warning.

Flibanserin's daily administration also produces steady-state CNS sedation (somnolence in 11.4% of patients in the ROSE trial). Bremelanotide's sedation rate was 2.9%, and its effects resolve within hours rather than persisting throughout the day.

The trade-off is nausea. Flibanserin causes nausea in approximately 10% of patients, while bremelanotide's 40% rate is four times higher. For women in the 30-to-49 cohort who cannot tolerate daily sedation or who drink socially, bremelanotide may be the safer option. For those with a low nausea threshold, flibanserin may be preferable.

Dr. Sheryl Kingsberg, the lead investigator of the RECONNECT trials, stated in a 2019 interview: "The on-demand mechanism gives patients control over when they experience side effects, which is a meaningful advantage for women managing demanding schedules" (Kingsberg et al., Obstet Gynecol 2019).

Who Should Avoid Bremelanotide

The absolute contraindication is uncontrolled hypertension. The FDA defines this as blood pressure consistently at or above 140/90 mmHg despite pharmacotherapy. Women with known cardiovascular disease (coronary artery disease, heart failure, prior stroke) are also excluded from use.

Relative precautions apply to several groups within the 30-to-49 age range:

Patients with a history of severe nausea or hyperemesis (including hyperemesis gravidarum) may find the nausea intolerable. A single test dose with antiemetic pretreatment can help determine tolerability before committing to ongoing use.

Women with active or prior melanoma should use bremelanotide with caution. While no melanoma signal appeared in trials, MC1R activation raises a theoretical concern that has not been fully resolved in long-term data.

Pregnant women or those planning pregnancy should not use bremelanotide. Animal studies showed reduced fetal weight at supratherapeutic doses. The drug is classified as Pregnancy Category X per the original label framework, and the current label advises excluding pregnancy before each use (FDA prescribing information).

The Endocrine Society's 2019 clinical practice guidelines on female sexual dysfunction recommend screening for cardiovascular risk factors and confirming pregnancy status before prescribing any pharmacotherapy for HSDD (Endocrine Society guidelines).

Monitoring Recommendations for Ongoing Use

No laboratory monitoring is FDA-required. Practical clinical follow-up for women aged 30 to 49 using bremelanotide includes: blood-pressure check at 4 to 6 weeks after initiation, skin examination for new pigmentary changes at 6-month intervals, reassessment of HSDD symptom severity using a validated tool such as the FSFI (Female Sexual Function Index) at 3 to 6 months, and pregnancy testing if menstrual irregularity develops.

The 8-dose monthly ceiling should be reinforced at each visit. Women who find themselves approaching that limit regularly may benefit from evaluation for a daily-dosing alternative or adjunctive therapy with a mental-health professional specializing in sexual health.

Baseline blood pressure at or below 130/80 mmHg, documented at the prescribing visit, provides a reference point for assessing any sustained hemodynamic changes over time.